Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Brentuximab Vedotin
/ therapeutic use
Carboplatin
/ therapeutic use
Depsipeptides
/ therapeutic use
Etoposide
/ therapeutic use
Humans
Ifosfamide
/ therapeutic use
Ki-1 Antigen
Lymphoma, T-Cell, Peripheral
/ drug therapy
Neoplasm Recurrence, Local
/ drug therapy
Retrospective Studies
ICE
brentuximab vedotin
relapsed/refractory PTCL
romidepsin
salvage chemotherapy
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
31
08
2021
received:
16
04
2021
accepted:
12
10
2021
pubmed:
10
3
2022
medline:
29
7
2022
entrez:
9
3
2022
Statut:
ppublish
Résumé
Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. We report outcomes of Bv-ICE in CD30 (+) and Ro-ICE in CD30 (-) R/R PTCL treated in "Blinded for peer review" Cancer Center. We retrospectively identified R/R PTCL patients treated with BV-ICE or romidepsin-ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv-ICE and 7 with Ro-ICE. Bv-ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro-ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv-ICE and three treated with Ro-ICE received transplantation. In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.
Sections du résumé
BACKGROUND
Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL.
AIM
We report outcomes of Bv-ICE in CD30 (+) and Ro-ICE in CD30 (-) R/R PTCL treated in "Blinded for peer review" Cancer Center.
METHODS AND RESULTS
We retrospectively identified R/R PTCL patients treated with BV-ICE or romidepsin-ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv-ICE and 7 with Ro-ICE. Bv-ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro-ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv-ICE and three treated with Ro-ICE received transplantation.
CONCLUSION
In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.
Identifiants
pubmed: 35263030
doi: 10.1002/cnr2.1581
pmc: PMC9327648
doi:
Substances chimiques
Depsipeptides
0
Ki-1 Antigen
0
Etoposide
6PLQ3CP4P3
Brentuximab Vedotin
7XL5ISS668
Carboplatin
BG3F62OND5
romidepsin
CX3T89XQBK
Ifosfamide
UM20QQM95Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1581Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Blood. 2019 Oct 24;134(17):1395-1405
pubmed: 31471376
Blood. 2014 May 15;123(20):3095-100
pubmed: 24652992
J Clin Oncol. 2012 Feb 20;30(6):631-6
pubmed: 22271479
Acta Haematol. 2019;141(4):216-221
pubmed: 30943470
Expert Opin Biol Ther. 2019 Mar;19(3):197-209
pubmed: 30658046
J Hematol Oncol. 2016 Apr 12;9:38
pubmed: 27071522
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
Ann Oncol. 2003;14 Suppl 1:i5-10
pubmed: 12736224
Haematologica. 2018 Sep;103(9):e416-e418
pubmed: 29622656
Leuk Lymphoma. 2017 Jun;58(6):1349-1357
pubmed: 28103725
J Clin Oncol. 2013 Jun 1;31(16):1970-6
pubmed: 23610113
Clin Cancer Res. 2020 Mar 1;26(5):1000-1008
pubmed: 31772119
Leuk Lymphoma. 2019 Apr;60(4):912-919
pubmed: 30301414
Eur J Haematol. 2021 Apr;106(4):467-472
pubmed: 33320379
Blood. 2018 Jan 25;131(4):397-407
pubmed: 29141948
Br J Dermatol. 2019 Dec;181(6):1315-1317
pubmed: 31206589
Lancet Oncol. 2018 Feb;19(2):257-266
pubmed: 29276022
Cancer Rep (Hoboken). 2022 Jul;5(7):e1581
pubmed: 35263030
Eur J Haematol. 2020 Mar;104(3):251-258
pubmed: 31838747